Show simple item record

dc.contributor.authorLinfante, Italo
dc.contributor.authorAkkawi, Nabil M.
dc.contributor.authorPerlow, Alain
dc.contributor.authorAndreone, Vincenzo
dc.contributor.authorWakhloo, Ajay K.
dc.date2022-08-11T08:09:35.000
dc.date.accessioned2022-08-23T16:36:33Z
dc.date.available2022-08-23T16:36:33Z
dc.date.issued2005-07-30
dc.date.submitted2009-03-31
dc.identifier.citationStroke. 2005 Sep;36(9):1948-53. Epub 2005 Jul 28. <a href="http://dx.doi.org/10.1161/01.STR.0000177532.94736.85">Link to article on publisher's site</a>
dc.identifier.issn1524-4628 (Electronic)
dc.identifier.doi10.1161/01.STR.0000177532.94736.85
dc.identifier.pmid16051893
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38810
dc.description.abstractBACKGROUND AND PURPOSE: Recanalization of cerebral aneurysm is a limitation of bare platinum coils (BPCs). In a swine aneurysm model, polyglycolide/polylactide (a polymer)-coated platinum coils (Matrix) accelerated clot fibrosis and reduced recanalization rate and aneurysmal volume. We aimed to evaluate the safety of Matrix coils in patients with intracranial aneurysm. METHODS: This is a single-center, prospective study of patients with intracranial aneurysms treated with Matrix alone or in combination with BPCs. Follow-up evaluation included a 1-month clinical evaluation and a 6- and 12-month clinical and angiographic examination. Primary adverse events included death, stroke, and permanent neurological deficits. RESULTS: Between May 2002 and January 2004, 52 patients (range 34 to 79 years of age; 38 females) were treated for 54 aneurysms (size 7.9+/-4.6 mm; neck 3.9+/-1.5 mm; 26 ruptured). Matrix alone was used in 13 aneurysms. In 39, we used a combination of Matrix and BPCs. Twenty-one aneurysms had a 6-month follow-up examination (11 Matrix; 10 Matrix combined with bare platinum), and 11 completed the 12-month follow-up evaluation (Matrix only). Adverse events not related to the procedure were 2 deaths (ruptured basilar aneurysms) and 1 stroke at day 10 postcoiling secondary to vasospasm. Procedure-related adverse events were 2 strokes. At 6-month follow-up (n=21) evaluation, 2 of 3 recanalizations needed retreatment. At 12-month follow-up (n=11), there was no recanalization in patients treated with Matrix alone and no significant reduction in aneurysmal size. CONCLUSIONS: Polyglycolide/polylactide-coated coils had a satisfactory safety profile. Significant aneurysmal size reduction after coiling was not observed.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=16051893&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectAdult
dc.subjectAged
dc.subjectAneurysm, Ruptured
dc.subjectBiocompatible Materials
dc.subjectCerebral Angiography
dc.subjectCohort Studies
dc.subjectEmbolization, Therapeutic
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectInflammation
dc.subjectIntracranial Aneurysm
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPilot Projects
dc.subjectPolyesters
dc.subjectPolyglycolic Acid
dc.subjectPolymers
dc.subjectProspective Studies
dc.subjectRecurrence
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titlePolyglycolide/polylactide-coated platinum coils for patients with ruptured and unruptured cerebral aneurysms: a single-center experience
dc.typeJournal Article
dc.source.journaltitleStroke; a journal of cerebral circulation
dc.source.volume36
dc.source.issue9
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2652&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1653
dc.identifier.contextkey805474
refterms.dateFOA2022-08-23T16:36:33Z
html.description.abstract<p>BACKGROUND AND PURPOSE: Recanalization of cerebral aneurysm is a limitation of bare platinum coils (BPCs). In a swine aneurysm model, polyglycolide/polylactide (a polymer)-coated platinum coils (Matrix) accelerated clot fibrosis and reduced recanalization rate and aneurysmal volume. We aimed to evaluate the safety of Matrix coils in patients with intracranial aneurysm. METHODS: This is a single-center, prospective study of patients with intracranial aneurysms treated with Matrix alone or in combination with BPCs. Follow-up evaluation included a 1-month clinical evaluation and a 6- and 12-month clinical and angiographic examination. Primary adverse events included death, stroke, and permanent neurological deficits. RESULTS: Between May 2002 and January 2004, 52 patients (range 34 to 79 years of age; 38 females) were treated for 54 aneurysms (size 7.9+/-4.6 mm; neck 3.9+/-1.5 mm; 26 ruptured). Matrix alone was used in 13 aneurysms. In 39, we used a combination of Matrix and BPCs. Twenty-one aneurysms had a 6-month follow-up examination (11 Matrix; 10 Matrix combined with bare platinum), and 11 completed the 12-month follow-up evaluation (Matrix only). Adverse events not related to the procedure were 2 deaths (ruptured basilar aneurysms) and 1 stroke at day 10 postcoiling secondary to vasospasm. Procedure-related adverse events were 2 strokes. At 6-month follow-up (n=21) evaluation, 2 of 3 recanalizations needed retreatment. At 12-month follow-up (n=11), there was no recanalization in patients treated with Matrix alone and no significant reduction in aneurysmal size. CONCLUSIONS: Polyglycolide/polylactide-coated coils had a satisfactory safety profile. Significant aneurysmal size reduction after coiling was not observed.</p>
dc.identifier.submissionpathoapubs/1653
dc.contributor.departmentDepartment of Radiology
dc.source.pages1948-53


Files in this item

Thumbnail
Name:
16051893.pdf
Size:
299.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record